SEC Company Response from DURECT CORP (DRRX) (CIK 0001082038) — Aug 12, 2021
DURECT CORP (DRRX) (CIK 0001082038)
Date: Aug. 12, 2021 · CIK: 0001082038 · Accession: 0000950123-21-010445
AI Filing Summary & Sentiment
File numbers found in text: 333-258333
Show Raw Text
CORRESP 1 filename1.htm drrx-corresp.htm August 12, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Christine Westbrook, Office of Life Sciences Re: DURECT Corporation Registration Statement on Form S-3 Filed July 30, 2021 File No. 333-258333 REQUEST FOR ACCELERATION OF EFFECTIVENESS Acceleration Request Requested Date: August 16, 2021 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, DURECT Corporation (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the Company’s Registration Statement on Form S-3 (File No. 333-258333) effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable. The Company hereby authorizes Stephen Thau, who is an attorney with the Company’s outside legal counsel, Orrick, Herrington & Sutcliffe LLP, to orally modify or withdraw this request for acceleration. The Company requests that it be notified of such effectiveness by a telephone call to Mr. Thau at (212) 506-5076. [Signature page follows] Sincerely, DURECT CORPORATION By: /s/ Michael H. Arenberg Name: Michael H. Arenberg Title: Chief Financial Officer cc: James E. Brown, DURECT Corporation Stephen Thau, Esq., Orrick, Herrington & Sutcliffe LLP